Loading
A phase 1/2 trial of Pembrolizumab, Ipilimumab, Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by Vyriad, Inc., active and no longer recruiting.
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors is a phase 1/2 interventional study registered as NCT03647163 by Vyriad, Inc., with 33 participants enrolled, started 2019-04-09 and due to reach its primary completion in 2025-07-31. Interventions recorded: VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab. Conditions listed: Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab.
Shares Ipilimumab, Nivolumab, Pembrolizumab.
Shares Ipilimumab, Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Ipilimumab, Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab, Pembrolizumab.
Shares Ipilimumab, Nivolumab, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/